Home > Search Results: Stevens, Don
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 2 records in 0.02 seconds.
Articles, 2 records found
Articles 2 records found  
1.
17 p, 1.2 MB Impact of Minimal Residual Disease on Progression-Free Survival Outcomes after Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study / Munir, Talha (St James's Hospital) ; Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Owen, Carolyn (Tom Baker Cancer Centre) ; Follows, George (Addenbrookes Hospital (Cambridge, Regne Unit)) ; Benjamini, Ohad (Sheba Medical Center) ; Janssens, Ann (UZ Leuven Gasthuisberg) ; Levin, Mark-David (Albert Schweitzer Hospital) ; Osterborg, Anders (Karolinska University Hospital and Karolinska Institutet (Suecia)) ; Robak, Tadeusz (Medical University of Lodz. Copernicus Memorial Hospital) ; Simkovic, Martin (University Hospital Hradec Kralove (República Txeca)) ; Stevens, Don (Norton Cancer Institute) ; Voloshin, Sergey (Russian Scientific and Research Institute of Hematology and Transfusiology) ; Vorobyev, Vladimir (S.P. Botkin Moscow City Clinical Hospital) ; Yagci, Munci (Gazi Universitesi Tip Fakultesi) ; Ysebaert, Loic (Institut Universitaire du Cancer Toulouse Oncopole) ; Qi, Keqin (Janssen Research & Development) ; Qi, Qianya (Janssen Research & Development) ; Parisi, Lori (Janssen Research & Development) ; Srinivasan, Srinivasan (Oncology Translational Research. Janssen Research & Development) ; Schuier, Natasha (Janssen Research & Development) ; Baeten, Kurt (Janssen Research & Development) ; Howes, Angela (Janssen Research & Development) ; Caces, Donne Bennett (Janssen Research & Development) ; Niemann, Carsten U (Rigshospitalet Copenhagen University Hospital) ; Kater, Arnon P. (Amsterdam Medical Centers. University of Amsterdam)
PURPOSEIn GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL). [...]
2023 - 10.1200/JCO.22.02283
Journal of Clinical Oncology, Vol. 41 Núm. 21 (20 2023) , p. 3689-3699  
Detailed record - Creative Commons
2.
9 p, 1.3 MB Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia : A cross-trial comparison of phase 3 studies / Robak, Tadeusz (Medical University of Lodz) ; Burger, Jan A. (The University of Texas MD Anderson Cancer Center) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ; Barr, Paul M. (University of Rochester Cancer Center) ; Owen, Carolyn (University of Calgary) ; Bairey, Osnat (Tel Aviv University) ; Hillmen, Peter (St. James's Institute of Oncology) ; Simpson, David (North Shore Hospital) ; Grosicki, Sebastian (Silesian Medical University) ; Devereux, Stephen (King's College Hospital NHS Foundation Trust) ; McCarthy, Helen (Royal Bournemouth Hospital) ; Coutre, Steven E (Stanford University School of Medicine) ; Quach, Hang (St. Vincent's Hospital) ; Gaidano, Gianluca (Amedeo Avogadro University of Eastern Piedmont) ; Maslyak, Zvenyslava (Institute of Blood Pathology and Transfusion Medicine of the Academy of Medical Sciences of Ukraine) ; Stevens, Don A. (Norton Cancer Institute) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Gill, Devinder S. (Princess Alexandra Hospital) ; Flinn, Ian W. (Sarah Cannon Research Institute/Tennessee Oncology) ; Gribben, John G. (Queen Mary University of London) ; Mokatrin, Ahmad (Pharmacyclics LLC. an AbbVie Company) ; Cheng, Mei (Pharmacyclics LLC. an AbbVie Company) ; Styles, Lori (Pharmacyclics LLC. an AbbVie Company) ; James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ; Kipps, Thomas J (University of California San Diego) ; Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele) ; Universitat Autònoma de Barcelona
Chemoimmunotherapy (CIT) and targeted therapy with single-agent ibrutinib are both recommended first-line treatments for chronic lymphocytic leukemia (CLL), although their outcomes have not been directly compared. [...]
2018 - 10.1002/ajh.25259
American Journal of Hematology, Vol. 93 Núm. 11 (november 2018) , p. 1402-1410  
Detailed record - Creative Commons

See also: similar author names
1 Stevens, D.
1 Stevens, D.A.
1 Stevens, Don A.
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with